Sofwave for upper arms: sessions, timing and FDA evidence
Published by Delight Dermatology editorial team ·
FDA 510(k) K233104 added improvement of the appearance of upper-arm skin laxity to the SofWave System's US indications. The clinical study summarized in that record used two sessions, 1–3 weeks apart, and assessed the primary result three months after the final session. Those details describe the documented upper-arm protocol; they do not guarantee an individual result.
What K233104 actually documents
The FDA's 510(k) summary identifies the added indication as improvement of the appearance of upper-arm skin laxity. The decision date is December 22, 2023. The record is a US regulatory document for a particular device and indication; it is not a general endorsement of every marketing statement made about upper-arm tightening.
| Question | What the record says | What it does not establish |
|---|---|---|
| Indication | Appearance of upper-arm skin laxity | Korean approval, clinic availability or superiority |
| Study schedule | Two sessions, 1–3 weeks apart | A universal schedule for every body area or indication |
| Primary assessment | Three months after the final session | A result that lasts indefinitely or is fixed for every patient |
How many Sofwave sessions are needed for upper arms?
The study used two sessions, 1–3 weeks apart. At a consultation, ask how the proposed number of sessions and interval relate to your treatment area. Check whether a quote covers one session or the full proposed plan.
For a broader description of the technology, see how Sofwave works. For screening factors, see candidates and contraindications.
How to read the follow-up timing
“Three months after final treatment” means the assessment clock starts after the second session in this study. It should not be shortened to three months after the first visit. It also describes the study's assessment point, not a promise that the visible response will begin, peak or last for the same period in every person.
Limits of the FDA record
K233104 documents a US device clearance and a defined study protocol. It does not establish Korean authorization or local availability, prove superiority over another device, set one schedule for every treatment area, or promise a particular result.
What to ask at a consultation
If you are considering upper-arm treatment in Seoul, ask about local authorization, device availability and the evidence supporting the proposed plan.
- Which indication and treatment area support the proposed schedule?
- Is the quote per session, and how many sessions are being proposed?
- When will the response be assessed, and what would count as a meaningful change?
- Which risks, exclusions and alternatives apply to the upper-arm area?
- Which device and treatment settings will be used?
Frequently asked questions
Is Sofwave FDA cleared for upper-arm skin laxity?
Yes. FDA K233104 lists improvement of the appearance of upper-arm skin laxity as the added indication. A 510(k) clearance is not a promise of a particular result and is not evidence of Korean approval or availability.
How many sessions were used in the upper-arm study?
The clinical study summarized in K233104 used two treatment sessions, scheduled 1–3 weeks apart. Ask which evidence and treatment area support the schedule proposed for you.
When was the upper-arm result assessed?
The primary follow-up described in the 510(k) summary was three months after the final treatment. This timing is measured from the second session, not from the first.
Does the FDA record prove that everyone improves?
No. The submission reports a study result under a defined protocol. It does not guarantee an individual outcome, establish a universal treatment plan, or show superiority over another device.
Can the upper-arm schedule be applied to the face or neck?
Not automatically. Session count and assessment timing must be read in the context of the indication and protocol. Evidence from the upper-arm study should not be generalized to every treatment area.
Primary source
- US Food and Drug Administration. K233104 510(k) summary for the SofWave System. Decision date December 22, 2023; indication on page 4 and clinical study schedule on pages 7–8.